UroGen Announces Results from Subgroup Analyses of the Pivotal ENVISION Trial Evaluating Impact of Baseline Tumor Burden and Focality on Response to UGN-102 [Yahoo! Finance]
UroGen Pharma Ltd. - Ordinary Shares (URGN)
Last urogen pharma ltd. - ordinary shares earnings: 3/2 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.urogen.com
Company Research
Source: Yahoo! Finance
Business Wire Fri, February 14, 2025 at 8:30 PM GMT+1 9 min read In This Article URGN Results presented at the American Society of Clinical Oncology's Genitourinary Cancers Symposium (ASCO GU 2025) Treatment with UGN-102 resulted in durable complete response (CR) rates across subgroups with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) CR rates were: 82.8% for patients with a tumor burden =3 cm compared to 73.2% for those with a tumor burden 3 cm 79.3% for patients with multiple tumors compared to 82.9% for those with single tumors CR rates and duration of response (DOR) patterns were similar across tumor burden and focality subgroups PRINCETON, N.J., February 14, 2025 BUSINESS WIRE )--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced results from the subgroup analyses of the pivotal ENVISION st
Show less
Read more
Impact Snapshot
Event Time:
URGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
URGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
URGN alerts
High impacting UroGen Pharma Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
URGN
News
- UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare ConferenceGlobeNewswire
- UroGen Pharma (URGN) Closes Q3 2025 With $127.4 Million in Cash Amid Rising R&D Costs [Yahoo! Finance]Yahoo! Finance
- Analysts Have Made A Financial Statement On UroGen Pharma Ltd.'s (NASDAQ:URGN) Third-Quarter Report [Yahoo! Finance]Yahoo! Finance
URGN
Earnings
- 11/6/25 - Beat
URGN
Analyst Actions
- 10/27/25 - HC Wainwright
URGN
Sec Filings
- 12/1/25 - Form 4
- 12/1/25 - Form 4
- 12/1/25 - Form 4
- URGN's page on the SEC website